Teva Plans To Launch Six Biosimilars By 2027

With US Approvals In Hand, Teva And Alvotech Take Aim At Adalimumab And Ustekinumab

 
• By David Wallace
Pencil drawing outline of number 2027
Teva has outlined plans for six biosimilar launches by 2027 • Source: Shutterstock

More from Biosimilars

More from Products